Holen Sie sich die Stockscreener-App
19.31
3.59%
-0.72
Handel nachbörslich:
19.69
0.38
+1.97%
Schlusskurs vom Vortag:
$20.03
Offen:
$20.01
24-Stunden-Volumen:
742.14K
Relative Volume:
0.87
Marktkapitalisierung:
$1.44B
Einnahmen:
$384.03M
Nettoeinkommen (Verlust:
$38.65M
KGV:
62.29
EPS:
0.31
Netto-Cashflow:
$196.35M
1W Leistung:
-2.92%
1M Leistung:
-6.89%
6M Leistung:
+0.52%
1J Leistung:
+11.10%
1-Tages-Spanne:
$19.26
$20.20
1-Wochen-Bereich:
$19.26
$20.23
52-Wochen-Spanne:
$16.52
$22.76
Innoviva Inc Stock (INVA) Company Profile
Firmenname
Innoviva Inc
Sektor
Branche
Telefon
(650) 238-9600
Adresse
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Vergleichen Sie INVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
19.31 | 1.50B | 384.03M | 38.65M | 196.35M | 0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Eingeleitet | Goldman | Sell |
| 2025-08-11 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-20 | Eingeleitet | Goldman | Neutral |
| 2017-11-20 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Innoviva Inc Aktie (INVA) Neueste Nachrichten
Synergy Asset Management LLC Invests $1.85 Million in Innoviva, Inc. $INVA - MarketBeat
Avoiding Lag: Real-Time Signals in (INVA) Movement - Stock Traders Daily
Innoviva’s Stock Under the Microscope: Is INVA Quietly Setting Up Its Next Move? - AD HOC NEWS
Innoviva joins elite list of stocks with 95-plus composite rating - MSN
Pacer Advisors Inc. Sells 48,889 Shares of Innoviva, Inc. $INVA - Defense World
Scotiabank Initiates Coverage of Innoviva (INVA) with Sector Outperform Recommendation - MSN
Is Innoviva Inc stock in correction or buying zoneJuly 2025 Reactions & Community Trade Idea Sharing Platform - moha.gov.vn
Despite Lower Earnings Than Five Years Ago, Innoviva (NASDAQ:INVA) Investors Are up 65% Since Then - 富途牛牛
Innoviva (INVA): Valuation Check After FDA Approval of First-in-Class NUZOLVENCE Antibiotic - Sahm
Innoviva (NASDAQ:INVA) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Is Innoviva Inc a good long term investmentMarket Sentiment Report & Small Investment Portfolio - earlytimes.in
December 2026 Options Now Available For Innoviva (INVA) - Nasdaq
How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug - Sahm
H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating - Finviz
Technical Reactions to INVA Trends in Macro Strategies - Stock Traders Daily
Will Innoviva Inc. stock attract ESG investorsTrade Exit Report & Daily Profit Maximizing Trade Tips - Улправда
Will Innoviva Inc. (HVE) stock justify high valuation2025 Volatility Report & Weekly Watchlist for Consistent Profits - Улправда
Will Innoviva Inc. (HVE) stock recover faster than industryJuly 2025 Short Interest & High Return Trade Guides - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Can Innoviva Inc. stock deliver surprise earnings beatMarket Growth Summary & Low Drawdown Momentum Ideas - Улправда
Aug Fed Impact: How Innoviva Inc. (HVE) stock compares with tech leadersInsider Selling & Short-Term High Return Ideas - Улправда
Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Weekly Recap & Daily Stock Trend Reports - Улправда
Is Innoviva Still Attractive Around $20 After Strong Multi Year Share Price Gains? - Yahoo Finance
How Innoviva Inc. stock responds to policy changesQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - DonanımHaber
Why Innoviva Inc. stock is in analyst buy zoneWeekly Risk Summary & Stock Portfolio Risk Control - DonanımHaber
Is Innoviva Inc. stock positioned for digital transformationJuly 2025 Patterns & Long-Term Capital Growth Strategies - DonanımHaber
Can Innoviva Inc. stock deliver sustainable ROENew Guidance & Low Risk Entry Point Guides - DonanımHaber
Profit Recap: Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Catalysts & Weekly Stock Performance Updates - Улправда
Will Innoviva Inc. stock see PE expansion2025 Performance Recap & Capital Efficiency Focused Ideas - Улправда
Innoviva, Inc. (NASDAQ:INVA) Receives $38.60 Average Target Price from Analysts - Defense World
HC Wainwright & Co. Maintains Innoviva (INVA) Buy Recommendation - Nasdaq
INVA: HC Wainwright & Co. Maintains Buy Rating and Raises Price Target | INVA Stock News - GuruFocus
Innoviva announces Lancet publication of 'positive' Zoliflodacin Phase 3 data - MSN
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - BioSpace
Innoviva Specialty Therapeutics announces FDA approval of Nuzolvence - MSN
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Innoviva (INVA): Revisiting Valuation After a Strong Multi‑Year Share Price Run - Sahm
US FDA approves Innoviva’s oral antibiotic for gonorrhea - WTAQ
US FDA approves Innoviva's oral antibiotic for gonorrhea - Reuters
Innoviva (NASDAQ: INVA) gets FDA approval for single-dose oral antibiotic NUZOLVENCE for gonorrhea - Stock Titan
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - BioSpace
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 - PharmiWeb.com
Trading the Move, Not the Narrative: (INVA) Edition - Stock Traders Daily
Innoviva, Inc. $INVA Shares Bought by Marshall Wace LLP - MarketBeat
State Board of Administration of Florida Retirement System Cuts Stake in Innoviva, Inc. $INVA - MarketBeat
Finanzdaten der Innoviva Inc-Aktie (INVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Innoviva Inc-Aktie (INVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DENNER ALEXANDER J | 10% Owner |
Mar 05 '25 |
Sale |
17.63 |
270,374 |
4,766,126 |
6,855,451 |
| DENNER ALEXANDER J | 10% Owner |
Mar 04 '25 |
Sale |
17.63 |
151,175 |
2,665,079 |
7,125,825 |
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):